Modulation of murine complement receptor type 2 (CR2/CD21) ectodomain shedding by its cytoplasmic domain

Molecular Immunology

Volumn 45, Issue 8, 2008, Pages 2127-2137

  Hoefer, Melanie M ^a   Aichem, Annette ^a   Knight, Andrew M ^b   Illges, Harald ^c  

^a UNIVERSITY OF KONSTANZ   (Switzerland)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

B cell activation; Complement receptor 2 CD21; Glutathione; Pervanadate; Shedding

Indexed keywords

ACETYLCYSTEINE; AMINO ACID; ANTIOXIDANT; CELL SURFACE PROTEIN; COMPLEMENT COMPONENT C3D RECEPTOR; COMPLEMENT RECEPTOR; COMPLEMENT RECEPTOR TYPE 2; GLUTATHIONE; PERVANADATE; PHOSPHATASE; THIOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL DIFFERENTIATION; CELL SURFACE; CONTROLLED STUDY; CYTOPLASM; CYTOSKELETON; DRUG EFFECT; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOFLUORESCENCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

AMINO ACID SEQUENCE; ANIMALS; ANTIOXIDANTS; B-LYMPHOCYTES; CYTOPLASM; FLUORESCENCE; MALE; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, COMPLEMENT 3D; SEQUENCE DELETION; SULFHYDRYL COMPOUNDS; TIME FACTORS; VANADATES;

MURINAE;

EID: 40149107261     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2007.12.015     Document Type: Article

References (57)

1. Aichem, A., Masilamani, M., Illges, H., 2006. Redox-regulation of CD21- shedding involves signaling via PKC and indicates the formation of a juxtamembrane stalk. J. Cell Sci. 119, 2892-2902.
2. Arens, R., Nolte, M.A., Tesselaar, K., Heemskerk, B., Reedquist, K.A., van Lier, R.A., van Oers, M.H., 2004. Signaling through CD70 regulates B cell activation and IgG production. J. Immunol. 173, 3901-3908.
3. Arribas, J., Merlos-Suarez, A., 2003. Shedding of plasma membrane proteins. In: Zucker, S., Chen, W.T. (Eds.), Current Topics in Developmental Biology-Cell Surface Proteases, vol. 54. Academic Press, pp. 125-144.
4. Arribas, J., Lopez-Casillas, F., Massague, J., 1997. Role of the juxtamembrane domains of the transforming growth factor-alpha precursor and the betaamyloid precursor protein in regulated ectodomain shedding. J. Biol. Chem. 272, 17160-17165.
5. Asokan, R., Hua, J., Young, K.A., Gould, H.J., Hannan, J.P., Kraus, D.M., Szakonyi, G., Grundy, G.J., Chen, X.S., Crow, M.K., Holers, V.M., 2006. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-{alpha}: a potential role in systemic lupus erythematosus. J. Immunol. 177, 383-394.
6. Axcrona, K., Gray, D., Leanderson, T., 1996. Regulation of B cell growth and differentiation via CD21 and CD40. Eur. J. Immunol. 26, 2203-2207.
7. Barrault, D.V., Knight, A.M., 2004. Distinct sequences in the cytoplasmic domain of complement receptor 2 are involved in antigen internalization and presentation. J. Immunol. 172, 3509-3517.
8. Baumgarth, N., 2000. A two-phase model of B-cell activation. Immunol. Rev. 176, 171-180.
9. Blobel, C.P., 2005. ADAMs: key components in EGFR signalling and development. Nat. Rev. Mol. Cell Biol. 6, 32-43.
10. Bonnefoy, J.Y., Lecoanet-Henchoz, S., Aubry, J.P., Gauchat, J.F., Graber, P., 1995. CD23 and B-cell activation. Curr. Opin. Immunol. 7, 355-359.
11. Bouillie, S., Barel, M., Frade, R., 1999. Signaling through the EBV/C3d receptor (CR2, CD21) in human B lymphocytes: activation of phosphatidylinositol 3-kinase via a CD19-independent pathway. J. Immunol. 162, 136-143.
12. Brummer, T., Elis, W., Reth, M., Huber, M., 2004. B-cell signal transduction: tyrosine phosphorylation, kinase activity, and calcium mobilization. Methods Mol. Biol. 271, 189-212.
13. Carroll, M.C., 2004. The complement system inBcell regulation. Mol. Immunol. 41, 141-146.
14. De Flora, S., Izzotti, A., D'Agostini, F., Balansky, R.M., 2001. Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points. Carcinogenesis 22, 999-1013.
15. Dello Sbarba, P., Rovida, E., 2002. Transmodulation of cell surface regulatory molecules via ectodomain shedding. Biol. Chem. 383, 69-83.
16. Faruki, S., Geahlen, R.L., Asai, D.J., 2000. Syk-dependent phosphorylation of microtubules in activated B-lymphocytes. J. Cell Sci. 113 (Pt 14), 2557-2565.
17. Fremeaux-Bacchi,V., Aubry, J.P., Bonnefoy, J.Y., Kazatchkine, M.D.,Kolb, J.P., Fischer, E.M., 1998a. Soluble CD21 induces activation and differentiation of human monocytes through binding to membrane CD23. Eur. J. Immunol. 28, 4268-4274.
18. Fremeaux-Bacchi, V., Fischer, E., Lecoanet-Henchoz, S., Mani, J.C., Bonnefoy, J.Y., Kazatchkine, M.D., 1998b. Soluble CD21 (sCD21) forms biologically active complexes with CD23: sCD21 is present in normal plasma as a complex with trimeric CD23 and inhibits soluble CD23-induced IgE synthesis by B cells. Int. Immunol. 10, 1459-1466.
19. Fremeaux-Bacchi, V., Kolb, J.P., Rakotobe, S., Kazatchkine, M.D., Fischer, E.M., 1999. Functional properties of soluble CD21. Immunopharmacology 42, 31-37.
20. Gill, M.B., Roecklein-Canfield, J., Sage, D.R., Zambela-Soediono, M., Longtine, N., Uknis, M., Fingeroth, J.D., 2004. EBV attachment stimulates FHOS/FHOD1 redistribution and co-aggregation with CD21: formin interactions with the cytoplasmic domain of human CD21. J. Cell Sci. 117, 2709-2720 (Epub May 11, 2004).
21. Gutwein, P., Mechtersheimer, S., Riedle, S., Stoeck, A., Gast, D., Joumaa, S., Zentgraf, H., Fogel, M., Altevogt, D.P., 2003. ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles. FASEB J 17, 292-294.
22. Hebell, T., Ahearn, J.M., Fearon, D.T., 1991. Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science 254, 102-105.
23. Heiz, M., Grunberg, J., Schubiger, P.A., Novak-Hofer, I., 2004. Hepatocyte growth factor-induced ectodomain shedding of cell adhesion molecule L1: role of the L1 cytoplasmic domain. J. Biol. Chem. 279, 31149-31156.
24. Hinkle, C.L., Diestel, S., Lieberman, J., Maness, P.F., 2006. Metalloproteaseinduced ectodomain shedding of neural cell adhesion molecule (NCAM). J. Neurobiol. 66, 1378-1395.
25. Hoefer, M.M., Illges, H., unpublished data.
26. Huemer, H.P., Larcher, C., Prodinger, W.M., Petzer, A.L., Mitterer, M., Falser, N., 1993. Determination of soluble CD21 as a parameter of B cell activation. Clin. Exp. Immunol. 93, 195-199.
27. Kinoshita, T., Takeda, J., Hong, K., Kozono, H., Sakai, H., Inoue, K., 1988. Monoclonal antibodies to mouse complement receptor type 1 (CR1). Their use in a distribution study showing that mouse erythrocytes and platelets are CR1-negative. J. Immunol. 140, 3066-3072.
28. Koka, S., Neudauer, C.L., Li, X., Lewis, R.E., McCarthy, J.B.,Westendorf, J.J., 2003. The formin-homology-domain-containing protein FHOD1 enhances cell migration. J. Cell Sci. 116, 1745-1755.
29. Kurtz, C.B., Paul, M.S., Aegerter,M.,Weis, J.J.,Weis, J.H., 1989. Murine complement receptor gene family. II. Identification and characterization of the murine homolog (Cr2) to human CR2 and its molecular linkage to Crry. J. Immunol. 143, 2058-2067.
30. Larcher, C., Kempkes, B., Kremmer, E., Prodinger, W.M., Pawlita, M., Bornkamm, G.W., Dierich, M.P., 1995. Expression of Epstein-Barr virus nuclear antigen-2 (EBNA2) induces CD21/CR2 on B and T cell lines and shedding of soluble CD21. Eur. J. Immunol. 25, 1713-1719.
31. Lowe, J., Brown, B., Hardie, D., Richardson, P., Ling, N., 1989. Soluble forms of CD21 and CD23 antigens in the serum in B cell chronic lymphocytic leukaemia. Immunol. Lett. 20, 103-109.
32. Masilamani, M., Apell, H.J., Illges, H., 2002. Purification and characterization of soluble CD21 from human plasma by affinity chromatography and density gradient centrifugation. J. Immunol. Methods 270, 11-18.
33. Masilamani, M., Kassahn, D., Mikkat, S., Glocker,M.O., Illges, H., 2003. B cell activation leads to shedding of complement receptor type II (CR2/CD21). Eur. J. Immunol. 33, 2391-2397.
34. Masilamani, M., Nowack, R., Witte, T., Schlesier, M., Warnatz, K., Glocker, M.O., Peter, H.H., Illges, H., 2004a. Reduction of soluble complement receptor 2/CD21 in systemic lupus erythomatosus and Sjogren's syndrome but not juvenile arthritis. Scand. J. Immunol. 60, 625-630.
35. Masilamani, M., von Kempis, J., Illges, H., 2004b. Decreased levels of serum soluble complement receptor-II (CR2/CD21) in patients with rheumatoid arthritis. Rheumatology (Oxford) 43, 186-190.
36. Mestas, J., Hughes, C.C., 2004. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172, 2731-2738.
37. Mignot, G., Roux, S., Thery, C., Segura, E., Zitvogel, L., 2006. Prospects for exosomes in immunotherapy of cancer. J. Cell Mol. Med. 10, 376-388.
38. Molina, H., Kinoshita, T., Inoue, K., Carel, J.C., Holers, V.M., 1990. A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2. J. Immunol. 145, 2974-2983.
39. Mukhopadhyay, A., Manna, S.K., Aggarwal, B.B., 2000. Pervanadate-induced nuclear factor-kappaB activation requires tyrosine phosphorylation and degradation of IkappaBalpha. Comparison with tumor necrosis factor-alpha. J. Biol. Chem. 275, 8549-8555.
40. Nagano, O., Saya, H., 2004. Mechanism and biological significance of CD44 cleavage. Cancer Sci. 95, 930-935.
41. Nemerow, G.R., Mullen 3rd, J.J., Dickson, P.W., Cooper, N.R., 1990. Soluble recombinant CR2 (CD21) inhibits Epstein-Barr virus infection. J. Virol. 64, 1348-1352.
42. Nishinaka, Y., Nakamura, H., Okada, N., Okada, H., Yodoi, J., 2001. Redox control of EBV infection: prevention by thiol-dependent modulation of functional CD21/EBV receptor expression. Antioxid. Redox Signal. 3, 1075-1087.
43. Overall, C.M., Blobel, C.P., 2007. In search of partners: linking extracellular proteases to substrates. Nat. Rev. Mol. Cell Biol. 8, 245-257.
44. Pastore, A., Federici, G., Bertini, E., Piemonte, F., 2003. Analysis of glutathione: implication in redox and detoxification. Clin. Chim. Acta 333, 19-39.
45. Pilzer, D., Gasser, O., Moskovich, O., Schifferli, J.A., Fishelson, Z., 2005. Emission of membrane vesicles: roles in complement resistance, immunity and cancer. Springer Semin. Immunopathol. 27, 375-387.
46. Qin, D., Wu, J., Carroll, M.C., Burton, G.F., Szakal, A.K., Tew, J.G., 1998. Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells and CD21 on B cells in the initiation of IgG responses. J. Immunol. 161, 4549-4554.
47. Ra, H.-J., Parks, W.C., 2007. Control of matrix metalloproteinase catalytic activity. Matrix Biol. 26, 587-596.
48. Reth, M., 2002. Hydrogen peroxide as second messenger in lymphocyte activation. Nat. Immunol. 3, 1129-1134.
49. Rickert, R.C., 2005. Regulation of B lymphocyte activation by complement C3 and the B cell coreceptor complex. Curr. Opin. Immunol. 17, 237-243.
50. Schlondorff, J., Blobel, C.P., 1999. Metalloprotease-disintegrins: modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding. J. Cell Sci. 112 (Pt. 21), 3603-3617.
51. Smalley, D.M., Ley, K., 2005. l-Selectin: mechanisms and physiological significance of ectodomain cleavage. J. Cell Mol. Med. 9, 255-266.
52. Stoeck, A., Keller, S., Riedle, S., Sanderson, M.P., Runz, S., Le Naour, F., Gutwein, P., Ludwig, A., Rubinstein, E., Altevogt, P., 2006. A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem. J. 393, 609-618.
53. Tedder, T.F., Haas, K.M., Poe, J.C., 2002. CD19-CD21 complex regulates an intrinsic Src family kinase amplification loop that links innate immunity with B-lymphocyte intracellular calcium responses. Biochem. Soc. Trans. 30, 807-811.
54. Tolnay, M., Vereshchagina, L.A., Tsokos, G.C., 2002. NF-kappaB regulates the expression of the human complement receptor 2 gene. J. Immunol. 169, 6236-6243.
55. Wienands, J., Larbolette, O., Reth, M., 1996. Evidence for a preformed transducer complex organized by the B cell antigen receptor. Proc. Natl. Acad. Sci. U.S.A. 93, 7865-7870.
56. Wienands, J., Schweikert, J.,Wollscheid, B., Jumaa, H., Nielsen, P.J., Reth, M., 1998. SLP-65: a new signaling component in B lymphocytes which requires expression of the antigen receptor for phosphorylation. J. Exp. Med. 188, 791-795.
57. Zandvoort, A., Timens,W., 2002. The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens. Clin. Exp. Immunol. 130, 4-11.